These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 31833196

  • 1. Progerin in muscle leads to thermogenic and metabolic defects via impaired calcium homeostasis.
    Wang WP, Wang JY, Lin WH, Kao CH, Hung MC, Teng YC, Tsai TF, Chi YH.
    Aging Cell; 2020 Feb; 19(2):e13090. PubMed ID: 31833196
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW, Glover TW.
    Hum Mol Genet; 2005 Oct 15; 14(20):2959-69. PubMed ID: 16126733
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
    Sánchez-López A, Espinós-Estévez C, González-Gómez C, Gonzalo P, Andrés-Manzano MJ, Fanjul V, Riquelme-Borja R, Hamczyk MR, Macías Á, Del Campo L, Camafeita E, Vázquez J, Barkaway A, Rolas L, Nourshargh S, Dorado B, Benedicto I, Andrés V.
    Circulation; 2021 Nov 30; 144(22):1777-1794. PubMed ID: 34694158
    [Abstract] [Full Text] [Related]

  • 6. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS.
    Proc Natl Acad Sci U S A; 2005 Sep 06; 102(36):12879-84. PubMed ID: 16129833
    [Abstract] [Full Text] [Related]

  • 7. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
    Yang SH, Qiao X, Farber E, Chang SY, Fong LG, Young SG.
    J Biol Chem; 2008 Mar 14; 283(11):7094-9. PubMed ID: 18178963
    [Abstract] [Full Text] [Related]

  • 8. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
    Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, López-Otín C, Andrés V.
    Circulation; 2013 Jun 18; 127(24):2442-51. PubMed ID: 23690466
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
    Eisch V, Lu X, Gabriel D, Djabali K.
    Oncotarget; 2016 Apr 26; 7(17):24700-18. PubMed ID: 27015553
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
    Kreienkamp R, Croke M, Neumann MA, Bedia-Diaz G, Graziano S, Dusso A, Dorsett D, Carlberg C, Gonzalo S.
    Oncotarget; 2016 May 24; 7(21):30018-31. PubMed ID: 27145372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann HP, Fong LG, Young SG.
    Hum Mol Genet; 2011 Feb 01; 20(3):436-44. PubMed ID: 21088111
    [Abstract] [Full Text] [Related]

  • 16. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
    Hamczyk MR, Andrés V.
    Nucleus; 2019 Dec 01; 10(1):28-34. PubMed ID: 30900948
    [Abstract] [Full Text] [Related]

  • 17. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells.
    Hamczyk MR, Villa-Bellosta R, Quesada V, Gonzalo P, Vidak S, Nevado RM, Andrés-Manzano MJ, Misteli T, López-Otín C, Andrés V.
    EMBO Mol Med; 2019 Apr 01; 11(4):. PubMed ID: 30862662
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.